ARGENX NV ADR

NASDAQ: ARGX (argenx SE)

Kemas kini terakhir: 3 hari lalu, 3:24AM

560.53

-7.53 (-1.33%)

  • 1H -1.33%
  • 5H 3.67%
  • 1B -3.51%
  • 6B -9.59%
  • Tahun Ke Tarikh -9.62%
  • 1T 29.09%
  • 5T 151.03%
Penutupan Terdahulu 568.06
Buka 560.06
Jumlah Dagangan 220,459
Purata Dagangan (3B) 407,379
Modal Pasaran 34,586,497,024
Harga / Pendapatan (P/E TTM) 34.14
Harga / Pendapatan (P/E Ke hadapan) 55.56
Harga / Jualan (P/S) 13.99
Harga / Buku (P/B) 6.01
Julat 52 Minggu
428.76 (-23%) — 678.21 (20%)
Tarikh Pendapatan 31 Jul 2025
Margin Keuntungan 40.26%
Margin Operasi (TTM) 17.50%
EPS Cair (TTM) 16.42
Pertumbuhan Hasil Suku Tahunan (YOY) 95.70%
Jumlah Hutang/Ekuiti (D/E MRQ) 0.71%
Nisbah Semasa (MRQ) 7.29
Aliran Tunai Operasi (OCF TTM) -82.75 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -143.39 M
Pulangan Atas Aset (ROA TTM) -0.21%
Pulangan Atas Ekuiti (ROE TTM) 17.36%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menurun Menurun
Biotechnology (Global) Menurun Menurun
Stok argenx SE Menaik Menaik

AISkor Stockmoo

1.1
Konsensus Penganalisis 4.0
Aktiviti Orang Dalam NA
Volatiliti Harga 2.0
Purata Bergerak Teknikal -1.0
Osilator Teknikal -0.5
Purata 1.13

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ARGX 35 B - 34.14 6.01
BMRN 10 B - 20.05 1.79
CRSP 4 B - - 2.10
EXEL 12 B - 19.94 5.51
CORT 8 B - 66.76 11.91
TGTX 6 B - 149.20 24.96

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Mid Growth
% Dimiliki oleh Institusi 55.50%
761.75761.75629.00629.00496.25496.25363.50363.50230.75230.75Harga Sasaran MedianQ3 '20Q3 '20Q4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
428.76 (-23%) — 678.21 (20%)
Julat Harga Sasaran
680.00 (21%) — 1,065.00 (-99%)
Tinggi 1,065.00 (Guggenheim, 90.00%) Beli
Median 717.50 (28.00%)
Rendah 680.00 (Baird, 21.31%) Beli
Purata 781.83 (39.48%)
Jumlah 6 Beli
Harga Purata @ Panggilan 555.74
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Wedbush 24 Jun 2025 715.00 (27.56%) Beli 568.06
11 Jun 2025 715.00 (27.56%) Beli 574.96
HC Wainwright & Co. 11 Jun 2025 720.00 (28.45%) Beli 574.96
10 Jun 2025 720.00 (28.45%) Beli 575.46
Baird 13 May 2025 680.00 (21.31%) Beli 542.47
Citigroup 09 May 2025 803.00 (43.26%) Beli 549.65
17 Apr 2025 796.00 (42.01%) Beli 596.20
Guggenheim 09 May 2025 1,065.00 (90.00%) Beli 549.65
Oppenheimer 09 May 2025 708.00 (26.31%) Beli 549.65

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
20 Jun 2025 Pengumuman argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
10 Jun 2025 Pengumuman argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease
03 Jun 2025 Pengumuman argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
28 May 2025 Pengumuman argenx Announces Results of Annual General Meeting of Shareholders
08 May 2025 Pengumuman argenx Reports First Quarter 2025 Financial Results and Provides Business Update
06 May 2025 Pengumuman argenx to Present at BofA Securities 2025 Health Care Conference
01 May 2025 Pengumuman argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
28 Apr 2025 Pengumuman argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11 Apr 2025 Pengumuman argenx Announces Annual General Meeting of Shareholders on May 27, 2025
10 Apr 2025 Pengumuman argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
08 Apr 2025 Pengumuman argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
Papar semua
588.05588.05568.48568.48548.91548.91529.33529.33509.76509.76Jun 13Jun 13Jun 16Jun 16Jun 17Jun 17Jun 18Jun 18Jun 20Jun 20Jun 23Jun 23Jun 24Jun 24Jun 25Jun 25

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
5.0005.0000.0000.000-5.000-5.000-10.000-10.000-15.000-15.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda